The results of a much-anticipated study, sponsored by semaglutide's maker Novo Nordisk, investigating the drug's effects on the heart were presented at the annual meeting of the American Heart Association in Philadelphia and published in the New England Journal of Medicine.
After more than three years, the scientists, led by Dr. A. Michael Lincoff, professor of medicine at the Cleveland Clinic, found that the people who received semaglutide lost about 9% of their body weight, compared to less than 1% in the placebo group. Those receiving semaglutide also reduced their risk of having a heart attack or stroke, or dying from a heart event, by 20%, compared to those receiving the placebo.
[
add
]
[
|
|
...
]